This report is the first in the literature to identify the IL-5 directed antibody, Mepolizumab, as a potential causative agent of Posterior Reversible Encephalopathy Syndrome (PRES) also known as Reversible Posterior Leukoencephalopathy [1–3]. Here, IL5 is linked to Posterior Leukoencephalopathy Syndrome.